Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1] Group 1: Class Action Details - Investors who purchased West Pharmaceutical common stock between February 16, 2023, and February 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 7, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4] Group 3: Case Allegations - The lawsuit alleges that West Pharmaceutical made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5] - It is claimed that West was experiencing significant destocking in its high-margin products, contrary to its public statements about strong visibility into customer demand [5] - The lawsuit also highlights operational inefficiencies that diluted profit margins and the risk of costly restructuring activities, including exiting contracts with long-standing customers [5]

PHILADELPHIA, June 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI) on behalf of purchasers of Compass securities between May 1, 2024 through May 7, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Compass securities during the Class Period may, no later than JULY 8, 2025, seek to be appointed as a lead plaintiff rep ...

SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company’s executives. Sookdeo v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05315 (N.D. Cal.) and Yaghsizian v. Hims & Hers Health, Inc. et al., No. 3:25-cv-05321 (N.D. Cal.). Together, the cases seek to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025. The ...

Core Viewpoint - PepGen Inc. is facing a securities fraud class action lawsuit alleging misrepresentations regarding the effectiveness and safety of its lead product candidate, PGN-EDO51, during a specified period [2][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased or acquired PepGen securities between March 7, 2024, and March 3, 2025 [2][3]. - Investors are reminded of an upcoming deadline to file as lead plaintiff by August 8, 2025, which allows them to represent other class members in the litigation [3]. Group 2: Legal Representation - Bernstein Liebhard LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [4]. - The firm has a strong track record, having recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its litigation success [5].

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, inclusive. For more information, submit a form at Sarepta Therapeutics, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb. ...

The US Supreme Court agreed to consider shielding Cox Communications from a $1 billion lawsuit by the music industry https://t.co/yCQZSnpfyN ...

NEW YORK, June 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Compass Group Diversified Holdings, LLC (NYSE: CODI).Shareholders who purchased shares of CODI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/compass-diversified-loss-submission-form/?id=154633&from=4CLASS PER ...

NEW YORK, June 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/rocket-pharmaceuticals-inc-loss-submission-form/?id=154643&from=4CLASS PERIO ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Iovance Biotherapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and a significant stock price decline following disappointing financial results [1][2]. Group 1: Allegations and Financial Performance - The class period for the allegations is from May 9, 2024, to May 8, 2025, during which Iovance allegedly provided overly positive statements while concealing material adverse facts about its growth potential [2]. - On July 25, 2024, Iovance announced its Q2 fiscal 2024 results and reduced its revenue guidance for the full fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of treatment initiation [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.795% in one day [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 14, 2025, to participate in the case without any cost or obligation [3]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit alleging misleading statements related to the company's cow's milk-based formula, Enfamil, which may have increased the risk of NEC in preterm infants [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from January 13, 2021, to July 28, 2024 [1]. - The complaint claims that Reckitt failed to disclose that preterm infants were at an increased risk of developing NEC from consuming Enfamil [1]. - It is alleged that Reckitt's positive statements about its business and operations were materially false and misleading due to the undisclosed risks and potential legal claims [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 4, 2025, to potentially become lead plaintiffs [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and illegal business practices [3]. - The firm is committed to ensuring companies engage in responsible business practices and good corporate citizenship [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated the company's stock [3].